References
- Spivak JL. Cancer-related anemia: its causes and characteristics. Semin Oncol 1994; 21: 3-8.
- Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998; 25: 43-6.
- Henry DH. The evolving role of epoetin alfa in cancer therapy. Oncologist 2004; 9: 97-107. https://doi.org/10.1634/theoncologist.9-1-97
- Goodnough LT. Erythropoietin therapy versus red cell transfusion. Curr Opin Hematol 2001; 8: 405-10. https://doi.org/10.1097/00062752-200111000-00015
- Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100: 2303-20. https://doi.org/10.1182/blood-2002-06-1767
- Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997; 15: 1218-34. https://doi.org/10.1200/JCO.1997.15.3.1218
- Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875-82. https://doi.org/10.1200/JCO.2001.19.11.2875
- Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-74. https://doi.org/10.1200/JCO.2001.19.11.2865
- Demetri GD, Gabrilove JL, Blasi MV, Hill RJ, Jr., Glaspy J. Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer 2002; 3: 45-51. https://doi.org/10.3816/CBC.2002.n.011
- FDA label information on ESA: http://wwwfdagov/cder/ drug/infopage/RHE/.
- Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 2001; 57: 411- 8. https://doi.org/10.1007/s002280100324
-
Ortho Biotech Products LP.
$Procrit^{\circledR}$ (epoetin alfa) prescribing information. Ortho Biotech Products, Raritan, NJ (March) 2007. - Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694-9. https://doi.org/10.1038/ki.1996.487
- Haurani FI, Green D, Young K. Iron Absorption in Hypoferremia. Am J Med Sci 1965; 249: 537-47. https://doi.org/10.1097/00000441-196505000-00007
- Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11: 530-8.
- Puglisi F, Deroma L, Russo S, et al. Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patients. Crit Rev Oncol Hematol 2009; 69: 175-82. https://doi.org/10.1016/j.critrevonc.2008.07.010
- Boccia R, Malik IA, Raja V, et al. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist 2006; 11: 409-17. https://doi.org/10.1634/theoncologist.11-4-409
- Cascinu S, Del Ferro E, Fedeli A, Ligi M, Alessandroni P, Catalano G. Recombinant human erythropoietin treatment in elderly cancer patients with cisplatinassociated anemia. Oncology 1995; 52: 422-6. https://doi.org/10.1159/000227501
- Massa E, Madeddu C, Lusso MR, Gramignano G, Mantovani G. Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Crit Rev Oncol Hematol 2006; 57: 175-82. https://doi.org/10.1016/j.critrevonc.2005.06.001
- Heras P, Argyriou AA, Papapetropoulos S, Karagiannis S, Argyriou K, Mitsibounas D. The impact of weekly dosing of epoetin alfa on the haematological parameters and on the quality of life of anaemic cancer patients. Eur J Cancer Care (Engl) 2005; 14: 108-12. https://doi.org/10.1111/j.1365-2354.2005.00571.x
- Lee YK, Kim SG, Seo JW, et al. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study. Nephrol Dial Transplant 2008; 23: 3240-6. https://doi.org/10.1093/ndt/gfn255